How does a psychiatrist choose which medication to prescribe?

A psychiatrist selects medication based on the specific diagnosis, symptom profile, co-occurring conditions, prior medication history (what has worked or failed), family history of medication response, side effect profile relative to patient characteristics (weight, cardiac health, sexual function priorities), potential drug interactions with current medications, pregnancy status or plans, pharmacogenomic testing results (when available), patient preferences, and cost/insurance coverage. Evidence-based guidelines inform first-line choices, but the 'best' medication varies by individual.

What is pharmacogenomic testing and should I get it?

Pharmacogenomic testing analyzes genetic variations that affect how your body metabolizes medications. Key genes tested include CYP2D6, CYP2C19, and CYP3A4, which encode liver enzymes responsible for metabolizing many psychiatric medications. Results classify you as a poor, intermediate, extensive, or ultra-rapid metabolizer. This information can explain why certain medications cause excessive side effects (poor metabolizers) or seem ineffective (ultra-rapid metabolizers). Testing is most useful when a patient has failed multiple medication trials or experienced unusual side effects. It is a tool that informs rather than dictates prescribing decisions.

How long do I need to stay on psychiatric medication?

This depends on the condition and clinical context. For a first episode of depression, guidelines recommend continuing medication for at least 6-12 months after remission. For recurrent depression (3+ episodes), long-term or indefinite treatment is often recommended. For ADHD, medication is typically continued as long as it provides benefit. For bipolar disorder, long-term mood stabilizer treatment is the standard of care. For anxiety disorders, at least 12 months after remission is recommended. Any discontinuation should be done gradually under psychiatric supervision to minimize withdrawal symptoms and relapse risk.

What are the most common side effects of psychiatric medications?

Side effects vary by medication class. SSRIs/SNRIs: nausea (usually temporary), sexual dysfunction, weight changes, insomnia or drowsiness. Stimulants: decreased appetite, insomnia, increased heart rate, anxiety. Mood stabilizers: weight gain (lithium, valproate), tremor (lithium), thyroid effects (lithium), teratogenicity (valproate). Atypical antipsychotics: weight gain, metabolic syndrome, sedation, akathisia. Benzodiazepines: sedation, cognitive impairment, dependence. Most side effects are manageable with dose adjustment, timing changes, or switching medications.

Is it safe to take multiple psychiatric medications at once?

Taking multiple psychiatric medications (polypharmacy) is sometimes necessary and appropriate -- for example, a mood stabilizer plus an antipsychotic for bipolar disorder, or an SSRI plus a stimulant for comorbid depression and ADHD. However, polypharmacy increases the risk of drug interactions, cumulative side effects, and medication non-adherence. Every medication in a regimen should have a clear diagnostic indication and documented benefit. A skilled psychopharmacologist regularly reviews the medication list to ensure each medication is still needed and the overall regimen makes pharmacological sense.

What happens if I stop my psychiatric medication suddenly?

Abruptly stopping psychiatric medication can cause discontinuation syndrome (SSRIs/SNRIs: dizziness, nausea, brain zaps, irritability, insomnia), withdrawal (benzodiazepines: seizures, anxiety rebound, potentially life-threatening), rebound symptoms (return of the condition being treated, sometimes worse than baseline), and mood destabilization (mood stabilizers: risk of manic or depressive episode). Always taper psychiatric medications gradually under medical supervision. Even medications not typically considered addictive (like SSRIs) can cause uncomfortable discontinuation symptoms if stopped abruptly.

When is medication appropriate versus therapy alone?

Therapy alone may be sufficient for mild to moderate depression, mild to moderate anxiety disorders, specific phobias, adjustment disorders, and relationship or situational issues. Medication is generally recommended (often combined with therapy) for moderate to severe depression, ADHD, bipolar disorder, schizophrenia and psychotic disorders, severe anxiety disorders, OCD, and conditions that have not responded to therapy alone. For many conditions, the combination of medication and therapy produces better outcomes than either alone.

Home → Medication Management

Psychiatric Medication Management: A Psychopharmacology Expert's Guide

Creator: Ryan S. Sultan, MD
Published: 2026-03-29
Keywords: psychopharmacology, medication management, psychiatric medications, antidepressants, stimulants, mood stabilizers

By Ryan S. Sultan, MD
Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Board-Certified in Adult Psychiatry and Child & Adolescent Psychiatry
NIH NIDA K12 Researcher
March 29, 2026

Psychiatric medication management requires expert knowledge of psychopharmacology -- the science of how medications affect the brain and behavior. Dr. Ryan Sultan at Columbia University provides evidence-based psychopharmacology at Integrative Psych in Manhattan, drawing on his NIH-funded research background and JAMA-published studies on prescribing patterns to ensure patients receive the right medication at the right dose with appropriate monitoring.

Quick Summary: Psychopharmacology is the branch of psychiatry dealing with the use of medications to treat mental health conditions. The field encompasses antidepressants, stimulants, mood stabilizers, antipsychotics, anxiolytics, and sleep aids. Effective medication management involves much more than simply choosing a drug and writing a prescription -- it requires understanding pharmacokinetics and pharmacodynamics, anticipating and managing side effects, navigating drug interactions, considering pharmacogenomics, developing augmentation strategies for treatment-resistant cases, and knowing when to add, change, combine, or discontinue medications. This guide covers each major medication class, how psychiatrists make prescribing decisions, and what patients should know about their treatment.

What Is Psychopharmacology?

Psychopharmacology is the study of how medications affect mood, thinking, behavior, and brain function. As a discipline, it sits at the intersection of neuroscience, pharmacology, and clinical medicine. A psychopharmacologist is a psychiatrist with particular expertise in the selection, dosing, and management of psychiatric medications -- especially for complex cases involving multiple conditions, treatment resistance, or difficult-to-manage side effects.

This is where the difference between a general prescriber and a specialist becomes critical. Any physician can write a prescription for an antidepressant. But understanding why one SSRI might work better than another for a particular patient, how to sequence medication trials, when to augment rather than switch, how to manage drug-drug interactions in a patient taking multiple medications, and how to interpret pharmacogenomic results -- that requires specialized training and experience.

My background in psychopharmacology is rooted in both clinical training and research. My JAMA Internal Medicine study on antipsychotic prescribing patterns -- cited over 411 times -- examined how psychiatric medications are being used in practice versus what the evidence supports. This research perspective makes me acutely aware of both the power and the limitations of psychiatric medications and drives my commitment to evidence-based, thoughtful prescribing.

Classes of Psychiatric Medications

Antidepressants

Antidepressants are among the most widely prescribed medications in the United States. While primarily used for depression, they are also first-line treatments for anxiety disorders, OCD, PTSD, and some chronic pain conditions.

SSRIs (Selective Serotonin Reuptake Inhibitors): The most commonly prescribed antidepressants. They work by blocking the reabsorption of serotonin in the brain, increasing serotonin availability in the synapse. Major SSRIs include fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), paroxetine (Paxil), citalopram (Celexa), and fluvoxamine (Luvox). Generally well-tolerated with common side effects including nausea, sexual dysfunction, weight changes, and insomnia or drowsiness. Take 4-6 weeks for full effect.

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): Block reuptake of both serotonin and norepinephrine. Include venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine (Pristiq), and levomilnacipran (Fetzima). Particularly useful for depression with prominent fatigue, pain syndromes, and anxiety. Can increase blood pressure at higher doses (especially venlafaxine).

Bupropion (Wellbutrin): Acts primarily on dopamine and norepinephrine. Unique among antidepressants in that it does not cause sexual dysfunction or weight gain -- in fact, it often reduces appetite. Also FDA-approved for smoking cessation. Contraindicated in eating disorders and seizure disorders due to dose-dependent seizure risk.

Mirtazapine (Remeron): Works through alpha-2 adrenergic antagonism and serotonin receptor modulation. Strongly sedating and appetite-stimulating, making it useful for depressed patients with insomnia and weight loss, but problematic for those already struggling with weight.

Tricyclic Antidepressants (TCAs): Older medications (amitriptyline, nortriptyline, imipramine, clomipramine) that affect serotonin, norepinephrine, and other receptor systems. Effective but with more side effects (sedation, dry mouth, constipation, cardiac effects, lethal in overdose) than newer options. Clomipramine remains important for treatment-resistant OCD.

MAOIs (Monoamine Oxidase Inhibitors): The oldest class (phenelzine, tranylcypromine, selegiline patch). Highly effective for treatment-resistant and atypical depression but require dietary restrictions (tyramine-containing foods can cause hypertensive crisis) and have significant drug interaction profiles. Reserved for patients who have failed multiple other antidepressant trials.

Stimulants and ADHD Medications

Stimulant medications are the most effective treatment for ADHD, with response rates of 70-80%. They work by increasing dopamine and norepinephrine availability in the prefrontal cortex, enhancing executive function, sustained attention, and impulse control.

Methylphenidate-based: Ritalin, Concerta, Focalin, Quillivant, Daytrana (patch). Available in immediate-release, extended-release, and long-acting formulations.

Amphetamine-based: Adderall, Vyvanse (lisdexamfetamine), Dexedrine. Vyvanse is a prodrug that is converted to active dextroamphetamine in the body, providing smoother onset and lower abuse potential.

Non-stimulant alternatives: Atomoxetine (Strattera, a norepinephrine reuptake inhibitor), guanfacine ER (Intuniv, an alpha-2 agonist), clonidine ER (Kapvay), and viloxazine (Qelbree). Used when stimulants are contraindicated, cause intolerable side effects, or when substance abuse risk is a concern.

For detailed information on ADHD medications, see my guides on ADHD Medications and Non-Stimulant ADHD Medications.

Mood Stabilizers

Mood stabilizers are the foundation of bipolar disorder treatment. Lithium, valproate (Depakote), lamotrigine (Lamictal), and carbamazepine (Tegretol) each have distinct efficacy profiles and monitoring requirements. Lithium is uniquely effective for reducing suicide risk. Lamotrigine is primarily effective for preventing bipolar depressive episodes. Valproate and carbamazepine are effective for acute mania and maintenance. For comprehensive coverage, see my page on Bipolar Disorder Treatment.

Antipsychotics

First-generation (typical) antipsychotics: Haloperidol (Haldol), chlorpromazine, perphenazine, fluphenazine. Effective for psychotic symptoms but carry higher risk of extrapyramidal side effects (EPS: dystonia, akathisia, parkinsonism) and tardive dyskinesia (involuntary movements with long-term use).

Second-generation (atypical) antipsychotics: Aripiprazole (Abilify), quetiapine (Seroquel), olanzapine (Zyprexa), risperidone (Risperdal), lurasidone (Latuda), cariprazine (Vraylar), brexpiprazole (Rexulti), ziprasidone (Geodon), clozapine (Clozaril), paliperidone (Invega). Used for schizophrenia, bipolar disorder, treatment-resistant depression (augmentation), and severe agitation. Lower risk of EPS than first-generation but carry metabolic risks (weight gain, diabetes, dyslipidemia) that require monitoring.

My JAMA research specifically examined patterns of antipsychotic prescribing -- including off-label use -- and highlighted the importance of appropriate metabolic monitoring. I approach antipsychotic prescribing with particular care, ensuring clear diagnostic indications, appropriate monitoring, and regular reassessment of ongoing need.

Anxiolytics

Benzodiazepines: Alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium). Fast-acting but carry dependence and tolerance risks. Appropriate for short-term use, acute crises, and specific situational anxiety.

Buspirone: Non-addictive anxiolytic for GAD. Requires consistent daily dosing (not effective as-needed). Takes 2-4 weeks for full effect.

Hydroxyzine: Antihistamine with anxiolytic properties. Non-addictive, works within an hour, but causes sedation.

Sleep Medications

Insomnia medications include melatonin receptor agonists (ramelteon), orexin receptor antagonists (suvorexant, lemborexant), Z-drugs (zolpidem, zaleplon, eszopiclone), low-dose trazodone, low-dose doxepin, and gabapentin. Each has a distinct mechanism and risk profile. Long-term use of Z-drugs and benzodiazepines for sleep is generally discouraged due to tolerance and dependence.

How Psychiatrists Choose Medications

Medication selection is not random. It follows a systematic process informed by evidence-based guidelines, clinical experience, and individual patient factors.

Factors I consider when choosing a medication:

Diagnosis and symptom profile: What condition am I treating? What are the predominant symptoms? For depression with insomnia and weight loss, mirtazapine makes sense. For depression with fatigue and pain, duloxetine is appropriate. For depression with comorbid ADHD, bupropion may address both.
Comorbid conditions: A patient with depression AND ADHD needs different consideration than one with depression alone. Bipolar disorder must be ruled out before starting an antidepressant.
Prior medication history: What has the patient tried before? What worked? What failed? What caused side effects? A medication that worked well for a family member has a higher likelihood of working for the patient.
Side effect profile: If a patient's primary concern is weight gain, I avoid medications known to cause it. If sexual dysfunction is a priority, bupropion or mirtazapine may be preferable to SSRIs.
Drug interactions: I review all current medications (including over-the-counter and supplements) for potential interactions. CYP450 enzyme interactions are particularly important -- some medications inhibit or induce liver enzymes that metabolize other medications, altering their blood levels.
Pharmacogenomics: When available, genetic testing results inform dosing and medication selection.
Age and medical history: Children, elderly patients, pregnant patients, and those with liver or kidney disease all require modified approaches.
Cost and access: The "best" medication is useless if the patient cannot afford it or obtain it. I consider insurance formularies and generic availability.

Pharmacogenomic Testing: Precision Medicine in Psychiatry

Pharmacogenomic testing analyzes genetic variations in enzymes that metabolize psychiatric medications. The most clinically relevant genes include CYP2D6 (metabolizes many antidepressants, antipsychotics, and some opioids), CYP2C19 (metabolizes certain antidepressants and benzodiazepines), CYP3A4 (metabolizes many medications across classes), SLC6A4 (serotonin transporter, may predict SSRI response), and HLA-A and HLA-B (predict risk of severe drug reactions, such as Stevens-Johnson syndrome with carbamazepine).

What the results mean:

Poor metabolizer: Medication builds up faster, increasing side effect risk. May need lower doses.
Intermediate metabolizer: Slightly slower metabolism. Standard or slightly lower doses often appropriate.
Normal (extensive) metabolizer: Standard dosing expected to work normally.
Ultra-rapid metabolizer: Medication is broken down too quickly, potentially reducing efficacy. May need higher doses or alternative medications.

I use pharmacogenomic testing selectively -- particularly when a patient has failed multiple medication trials, experienced unusual side effects, or has a family history suggesting atypical medication responses. The test results are one factor among many in prescribing decisions, not a replacement for clinical judgment.

Managing Side Effects

Side effects are one of the most common reasons patients discontinue psychiatric medications. A skilled psychopharmacologist can often manage side effects without switching medications.

Common strategies:

Dose adjustment: Many side effects are dose-dependent. Reducing the dose slightly while maintaining efficacy is often possible.
Timing changes: Moving a medication from morning to evening (or vice versa) can address insomnia or daytime sedation.
Adding a corrective: For SSRI-induced sexual dysfunction, bupropion augmentation or buspirone can help. For stimulant-induced insomnia, melatonin or clonidine at bedtime may be appropriate.
Slow titration: Starting at a low dose and increasing gradually reduces the likelihood and severity of initial side effects.
Formulation change: Extended-release formulations often produce fewer peak-and-trough side effects than immediate-release versions.
Patient education: Some side effects are transient (SSRI nausea typically resolves within 1-2 weeks). Knowing this helps patients persist through the initial adjustment period rather than discontinuing prematurely.

Augmentation Strategies for Treatment Resistance

When a first-line medication provides partial but insufficient response, augmentation -- adding a second medication -- is often more effective than switching to a different medication entirely.

Evidence-based augmentation strategies:

For depression: Adding aripiprazole, brexpiprazole, or quetiapine XR to an SSRI/SNRI (FDA-approved augmentation). Adding bupropion to an SSRI. Adding lithium (one of the oldest and best-studied augmentation strategies). Adding thyroid hormone (T3/liothyronine).
For OCD: Adding a low-dose antipsychotic (aripiprazole, risperidone) to an SSRI at maximum dose.
For ADHD: Adding guanfacine or clonidine to a stimulant (particularly effective for residual hyperactivity, impulsivity, or sleep difficulties).
For bipolar depression: Adding lurasidone or quetiapine to a mood stabilizer.

Polypharmacy: When Multiple Medications Are Necessary (and When They Are Not)

Polypharmacy -- the use of multiple medications simultaneously -- is sometimes clinically necessary. A patient with bipolar disorder and comorbid ADHD may need a mood stabilizer, an atypical antipsychotic, and a stimulant. A patient with treatment-resistant depression may need an SSRI plus an augmenting agent. These combinations are evidence-based and appropriate.

Problematic polypharmacy occurs when medications are added without clear indication, when multiple medications from the same class are prescribed simultaneously without rationale, when nobody reviews the total medication list to assess for interactions, or when medications are continued indefinitely without reassessment.

I regularly review every patient's medication regimen to ensure each medication has a clear purpose, is at an appropriate dose, and is still needed. Simplifying an overly complex regimen -- often inherited from prior providers -- can improve both outcomes and quality of life.

Medication Changes and Tapering

Changing or discontinuing psychiatric medications requires careful planning. Abrupt discontinuation can cause discontinuation syndrome (SSRIs/SNRIs), withdrawal (benzodiazepines), rebound symptoms, or mood destabilization (mood stabilizers).

My approach to medication changes:

Cross-tapering: When switching from one medication to another in the same class, I gradually reduce the old medication while gradually introducing the new one, minimizing the gap in coverage.
Slow tapering: When discontinuing a medication, I reduce the dose gradually over weeks to months, depending on the medication, duration of use, and patient sensitivity. Benzodiazepine tapers may take 2-6 months for patients who have been on them long-term.
Monitoring: I see patients more frequently during medication transitions to monitor for withdrawal symptoms, symptom recurrence, or adverse effects from the new medication.
Patient education: Patients need to know what to expect -- what symptoms are normal during a transition and what warrants a phone call.

The Role of Research in Medication Decisions

As a researcher at Columbia University funded by the National Institute on Drug Abuse (NIDA), I stay current with the latest evidence on psychiatric medications. My JAMA Internal Medicine study on prescribing patterns demonstrated that real-world prescribing often diverges from evidence-based guidelines -- medications are used off-label without adequate evidence, metabolic monitoring is frequently inadequate, and medication regimens grow more complex than necessary.

This research perspective informs every prescribing decision I make. I do not prescribe based on pharmaceutical marketing, anecdotal experience, or clinical inertia. I prescribe based on what the evidence supports, adjusted for the individual patient in front of me.

When Medication Is Appropriate vs. Therapy Alone

Not every mental health condition requires medication. Evidence supports therapy alone for mild to moderate depression (CBT is as effective as medication for mild-moderate cases), mild to moderate anxiety disorders, specific phobias (exposure therapy is the primary treatment), adjustment disorders, relationship issues and interpersonal difficulties, and grief.

Medication is generally recommended -- often combined with therapy -- for moderate to severe depression, ADHD (stimulants are the most effective treatment), bipolar disorder (mood stabilizers are essential), schizophrenia and psychotic disorders, severe anxiety disorders, OCD (higher-dose SSRIs improve ERP therapy outcomes), and conditions not responding to therapy alone.

For many conditions, the combination of medication and therapy produces better outcomes than either alone. The STAR*D study for depression, the CAMS study for childhood anxiety, and the TADS study for adolescent depression all demonstrated the superiority of combined treatment.

Need Expert Medication Management?

Dr. Ryan Sultan provides comprehensive psychopharmacology at Integrative Psych in Manhattan. With research expertise in prescribing patterns and a commitment to evidence-based care, he specializes in complex cases, treatment resistance, and medication optimization.

Schedule a Consultation →